<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="editorial"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Korean Med Sci</journal-id><journal-id journal-id-type="iso-abbrev">J. Korean Med. Sci</journal-id><journal-id journal-id-type="publisher-id">JKMS</journal-id><journal-title-group><journal-title>Journal of Korean Medical Science</journal-title></journal-title-group><issn pub-type="ppub">1011-8934</issn><issn pub-type="epub">1598-6357</issn><publisher><publisher-name>The Korean Academy of Medical Sciences</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29915527</article-id><article-id pub-id-type="pmc">PMC6000598</article-id><article-id pub-id-type="doi">10.3346/jkms.2018.33.e196</article-id><article-categories><subj-group subj-group-type="heading"><subject>Editorial</subject></subj-group></article-categories><title-group><article-title>Beta Blockers in Heart Failure: More Evidence for an Old Friend</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-7065-3432</contrib-id><name><surname>Baek</surname><given-names>Sang Hong</given-names></name><xref ref-type="aff" rid="A1"/></contrib></contrib-group><aff id="A1">Cardiovascular Medicine Division, Department of Internal Medicine, The Catholic University of Korea, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, <country>Korea</country>.</aff><author-notes><corresp>Address for Correspondence: Sang Hong Baek, MD, PhD.Cardiovascular Medicine Division, Department of Internal Medicine, The Catholic University of Korea, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul 06591, Korea. <email>whitesh@catholic.ac.kr</email></corresp></author-notes><pub-date pub-type="epub"><day>05</day><month>6</month><year>2018</year></pub-date><pub-date pub-type="collection"><day>18</day><month>6</month><year>2018</year></pub-date><volume>33</volume><issue>25</issue><elocation-id>e196</elocation-id><history><date date-type="received"><day>21</day><month>5</month><year>2018</year></date><date date-type="accepted"><day>25</day><month>5</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9; 2018 The Korean Academy of Medical Sciences.</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>The Korean Academy of Medical Sciences</copyright-holder><license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><related-article related-article-type="commentary-article" id="RA1" vol="33" elocation-id="e171" ext-link-type="pmc"><article-title>Impact of Heart Rate Reduction with Maximal Tolerable Dose of Bisoprolol on Left Ventricular Reverse Remodeling</article-title></related-article></article-meta></front><body><p>High resting heart rate (&#x02265; 70 bpm) was common in heart failure with reduced ejection fraction (HFrEF; ejection fraction &#x02264; 35%) patients and is associated with adverse outcomes in a real-world analysis. For heart failure (HF) hospitalization, hazard appeared to be more closely associated with heart rate rather than &#x003b2;-blocker dose.<xref rid="B1" ref-type="bibr">1</xref></p><p>Chronic &#x003b2;1-adrenergic receptor overactivation is well known to be an important component of pathologic ventricular remodeling, and evidence-based &#x003b2;-blockers are a clinically effective treatment of HFrEF owing in part to their reverse-remodeling effect. Current HF guidelines recommend the use of &#x003b2;-blockers based on many randomized controlled trials showing a reduced mortality rate &#x0003e; 35%. Although the beneficial effect of &#x003b2;-blocker seems undisputed, whether the target heart rate or target dose is more important in &#x003b2;-blocker therapy is the subject of debate. Meta-analysis showed that heart rate should be considered more important than the actual dose when tailoring &#x003b2;-blocker therapy. In particular, the target resting heart rate might be &#x0003c; 70 beats/min in HF patients. The reason why heart rate reduction is more important than &#x003b2;-blocker dose might be related to the large pharmacogenomic heterogeneity of &#x003b2;-blockers.<xref rid="B2" ref-type="bibr">2</xref></p><p>In the current issue, Choi et al.<xref rid="B3" ref-type="bibr">3</xref> concluded that high baseline HR (&#x02265; 75 bpm) showed an association with left ventricular reverse remodeling (LVRR) and improvement of NT-proBNP and global assessment score in patients with HFrEF &#x0003c; 40% at baseline and 6-months (n = 157). LVRR was identified in 49 patients (32%) and patients with ischemic etiology of HF were 19%. They suggest that this effect seems to be due to a large HR reduction after treatments with bisoprolol.</p><p>There are current challenges in the management of HF with &#x003b2;-blockers. Could we predict who would be the responder or non-responder of evidence-based &#x003b2;-blockers in HFrEF? Could we also predict who would be reverse-remodeling responders or not with &#x003b2;-blockers in HFrEF? Those are a couple of important questions in HF clinical practice.</p><p>The ST2-R2 score was recently developed to predict relevant LVRR in patients with HF. The ST2-R2 score includes the biomarker ST2 (&#x0003c; 48 ng/mL), and five conventional risk parameters (non-ischemic etiology, absence of left bundle branch block, HF duration [&#x0003c; 12 months], baseline LVEF [&#x0003c; 24%], and &#x003b2;-blocker treatment). However, more solid clinical outcome evidence would be necessary for generalizing the usage of the ST2-R2 score in HF clinic.<xref rid="B4" ref-type="bibr">4</xref></p><p>The phamarcogenomic clinical study using bisoprolol in Korean HF patients showed the ADRB1 Gly389X genotype showed a greater response to bisoprolol than the Arg389Arg genotype. However, there were no significant differences in LVEF changes or remodeling between Arg389Arg genotype group and Gly389X (Gly389Arg + Gly389Gly) group because of the small sample size. However, this result suggested the potential of individually tailoring &#x003b2;-blocker therapy according to genotype.<xref rid="B5" ref-type="bibr">5</xref></p><p>Although the exact mechanism of LVRR is still unknown, Sucharov et al.<xref rid="B6" ref-type="bibr">6</xref> reported a difference in gene expression including &#x003b2;-myosin heavy chain (MYH7) and atrial natriuretic peptide (NPPA) between those with LVRR (+) and LVRR (&#x02212;). Reverse-remodeling is accompanied by normalization of certain pathological changes in ventricular myocardial gene expression, the origins of which are incompletely understood. Such gene expressions regulate calcium-handling, sarcomeric/adrenergic signaling and consequently associate with LVRR. The expression of microRNAs is also altered in dilated cardiomyopathy. The myocardial microRNAs might predict the time-dependent reverse-remodeling response to &#x003b2;-blocker treatment, in dilated cardiomyopathy. More studies are necessary to confirm the specific reverse-remodeling-associated microRNAs as described.</p><p>In conclusion, it is clinically important to predict &#x003b2;-blocker responders and reverse-remodeling responders with &#x003b2;-blocker in HFrEF. The precision medicine using microRNA strategy would allow us to better understand the therapeutic response of &#x003b2;-blocker in HFrEF in the future.</p></body><back><fn-group><fn fn-type="COI-statement"><p><bold>Conflict of Interest:</bold> The author has no potential conflicts of interest to disclose.</p></fn></fn-group><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ibrahim</surname><given-names>N</given-names></name><name><surname>Gaggin</surname><given-names>HK</given-names></name><name><surname>Turchin</surname><given-names>A</given-names></name><name><surname>Patel</surname><given-names>HK</given-names></name><name><surname>Song</surname><given-names>Y</given-names></name><name><surname>Trebnick</surname><given-names>A</given-names></name><etal/></person-group><article-title>Heart rate, beta-blocker use, and outcomes of heart failure with reduced ejection fraction</article-title><source>Eur Heart J Cardiovasc Pharmacother</source><year>2018</year><comment>DOI: <ext-link ext-link-type="doi" xlink:href="10.1093/ehjcvp/pvy011">10.1093/ehjcvp/pvy011</ext-link></comment></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>HY</given-names></name><name><surname>Baek</surname><given-names>SH</given-names></name></person-group><article-title>Optimal use of beta-blockers for congestive heart failure</article-title><source>Circ J</source><year>2016</year><volume>80</volume><issue>3</issue><fpage>565</fpage><lpage>571</lpage><pub-id pub-id-type="pmid">26902451</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>S</given-names></name><name><surname>Han</surname><given-names>S</given-names></name><name><surname>Shim</surname><given-names>WJ</given-names></name><name><surname>Choi</surname><given-names>DJ</given-names></name><name><surname>Kim</surname><given-names>YJ</given-names></name><name><surname>Yoo</surname><given-names>BS</given-names></name><etal/></person-group><article-title>Impact of heart rate reduction with maximal tolerable dose of bisoprolol on left ventricular reverse remodeling</article-title><source>J Korean Med Sci</source><year>2018</year><volume>33</volume><issue>25</issue><elocation-id>e171</elocation-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lup&#x000f3;n</surname><given-names>J</given-names></name><name><surname>Sanders-van Wijk</surname><given-names>S</given-names></name><name><surname>Januzzi</surname><given-names>JL</given-names></name><name><surname>de Antonio</surname><given-names>M</given-names></name><name><surname>Gaggin</surname><given-names>HK</given-names></name><name><surname>Pfisterer</surname><given-names>M</given-names></name><etal/></person-group><article-title>Prediction of survival and magnitude of reverse remodeling using the ST2-R2 score in heart failure: A multicenter study</article-title><source>Int J Cardiol</source><year>2016</year><volume>204</volume><fpage>242</fpage><lpage>247</lpage><pub-id pub-id-type="pmid">26682955</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>HY</given-names></name><name><surname>Chung</surname><given-names>WJ</given-names></name><name><surname>Jeon</surname><given-names>HK</given-names></name><name><surname>Seo</surname><given-names>HS</given-names></name><name><surname>Choi</surname><given-names>DJ</given-names></name><name><surname>Jeon</surname><given-names>ES</given-names></name><etal/></person-group><article-title>Impact of the &#x003b2;-1 adrenergic receptor polymorphism on tolerability and efficacy of bisoprolol therapy in Korean heart failure patients: association between &#x003b2; adrenergic receptor polymorphism and bisoprolol therapy in heart failure (ABBA) study</article-title><source>Korean J Intern Med</source><year>2016</year><volume>31</volume><issue>2</issue><fpage>277</fpage><lpage>287</lpage><pub-id pub-id-type="pmid">26879662</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sucharov</surname><given-names>CC</given-names></name><name><surname>Kao</surname><given-names>DP</given-names></name><name><surname>Port</surname><given-names>JD</given-names></name><name><surname>Karimpour-Fard</surname><given-names>A</given-names></name><name><surname>Quaife</surname><given-names>RA</given-names></name><name><surname>Minobe</surname><given-names>W</given-names></name><etal/></person-group><article-title>Myocardial microRNAs associated with reverse remodeling in human heart failure</article-title><source>JCI Insight</source><year>2017</year><volume>2</volume><issue>2</issue><elocation-id>e89169</elocation-id><pub-id pub-id-type="pmid">28138556</pub-id></element-citation></ref></ref-list></back></article>
